Post-marketing Study Design to Evaluate the Effectiveness of the 9-valent and 4-valent HPV Vaccines on Serious HPV-related Cervical Disease in China

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2024 Oct 24

PMID 39445828

Authors

Yu Yang

Liang Zhang

Susanne Hartwig

Peng Jiang

Houyu Zhao

Ruogu Meng

Zhike Liu

Zuoxiang Liu

Keqin Ding

Xuedan You

Carol Koro

Guozhang Xu

Siyan Zhan

Affiliations

Soon will be listed here.

Abstract

The 4-valent (4 v) and 9-valent (9 v) human papillomavirus (HPV) vaccines are approved in China for females aged 9-45 years. However, the real-world impact of 4vHPV or 9vHPV vaccination for the prevention of high-grade cervical disease in Chinese women is lacking. Two post-marketing surveillance studies will be conducted to measure the occurrence of high-grade cervical lesions in Chinese women who had received ≥1 dose of the 4vHPV (aged 20-45 years) or 9vHPV (aged 16-26 years) vaccine in Ningbo, China. Vaccination data will be extracted from the Ningbo Regional Health Information Platform (NRHIP) from the date of the first 4vHPV (January 9, 2018) or the first 9vHPV (January 25, 2019) vaccination to March 31, 2021. The primary 4vHPV and 9vHPV vaccinated cohorts will include women vaccinated per protocol. The 4vHPV/9vHPV vaccinated test-negative (cervical HPV negative; ThinPrep cytology test negative) and corresponding matched unvaccinated HPV test-negative sub-cohorts will also be assessed. Outcomes will be the occurrence of new-onset cervical intraepithelial neoplasia grade 2/3, adenocarcinoma in situ, and invasive cervical cancer. This study aims to demonstrate that such a methodological approach is feasible and can be used to assess the impact of HPV vaccination in other regions across China.

Citing Articles

The impact of vaccine access difficulties on HPV vaccine intention and uptake among female university students in China.

Wang W Int J Equity Health. 2025; 24(1):4.

PMID: 39780149 PMC: 11715876. DOI: 10.1186/s12939-024-02370-6.

References

Wang W, Kothari S, Skufca J, Giuliano A, Sundstrom K, Nygard M . Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review. Expert Rev Vaccines. 2022; 21(12):1799-1817. DOI: 10.1080/14760584.2022.2129615. View

Ba D, McCall-Hosenfeld J, Ssentongo P, Chinchilli V, Agbese E, Liu G . Cervical cancer screening varies by HPV vaccination status among a National Cohort of privately insured young women in the United States 2006-2016. Medicine (Baltimore). 2021; 100(41):e27457. PMC: 8519251. DOI: 10.1097/MD.0000000000027457. View

de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56. DOI: 10.1016/S1470-2045(10)70230-8. View

Thamsborg L, Napolitano G, Larsen L, Lynge E . Impact of HPV vaccination on outcome of cervical cytology screening in Denmark-A register-based cohort study. Int J Cancer. 2018; 143(7):1662-1670. PMC: 6175001. DOI: 10.1002/ijc.31568. View

Benard V, Castle P, Jenison S, Hunt W, Kim J, Cuzick J . Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era. JAMA Oncol. 2016; 3(6):833-837. PMC: 5765871. DOI: 10.1001/jamaoncol.2016.3609. View

Markowitz L, Liu G, Hariri S, Steinau M, Dunne E, Unger E . Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics. 2016; 137(3):e20151968. DOI: 10.1542/peds.2015-1968. View

Brotherton J, Fridman M, May C, Chappell G, Saville A, Gertig D . Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011; 377(9783):2085-92. DOI: 10.1016/S0140-6736(11)60551-5. View

de Martel C, Georges D, Bray F, Ferlay J, Clifford G . Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2019; 8(2):e180-e190. DOI: 10.1016/S2214-109X(19)30488-7. View

Drolet M, Benard E, Perez N, Brisson M . Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; 394(10197):497-509. PMC: 7316527. DOI: 10.1016/S0140-6736(19)30298-3. View

10.

Rodriguez A, Zeybek B, Vaughn M, Westra J, Kaul S, Montealegre J . Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study. Cancer. 2020; 126(8):1656-1667. DOI: 10.1002/cncr.32700. View

11.

Ding L, Widdice L, Kahn J . Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction. Vaccine. 2017; 35(52):7217-7221. PMC: 5712261. DOI: 10.1016/j.vaccine.2017.11.005. View

12.

Dehlendorff C, Sparen P, Baldur-Felskov B, Herweijer E, Arnheim-Dahlstrom L, Ploner A . Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions. Vaccine. 2018; 36(43):6373-6378. DOI: 10.1016/j.vaccine.2018.09.011. View

13.

Thamsborg L, Napolitano G, Larsen L, Lynge E . High-grade cervical lesions after vaccination against human papillomavirus: A Danish cohort study. Acta Obstet Gynecol Scand. 2020; 99(10):1290-1296. PMC: 7540379. DOI: 10.1111/aogs.13935. View

14.

Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K . End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011; 105(1):28-37. PMC: 3137403. DOI: 10.1038/bjc.2011.185. View

15.

Welby S, Feng Y, Tang H, Ye C, Cohet C . A feasibility assessment of real-world data capabilities for monitoring vaccine safety and effectiveness in China: Human papillomavirus vaccination in the Yinzhou district as a use case. Pharmacoepidemiol Drug Saf. 2023; 32(10):1131-1141. DOI: 10.1002/pds.5644. View

16.

Kjaer S, Dehlendorff C, Belmonte F, Baandrup L . Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. J Natl Cancer Inst. 2021; 113(10):1329-1335. PMC: 8486335. DOI: 10.1093/jnci/djab080. View

17.

Meng R, Ma R, Wang J, Liu P, Liu Z, He B . Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine: a retrospective real-world study in China. Expert Rev Vaccines. 2023; 22(1):696-703. DOI: 10.1080/14760584.2023.2239911. View

18.

Wei L, Xie X, Liu J, Zhao Y, Chen W, Zhao C . Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up. Vaccine. 2018; 37(27):3617-3624. DOI: 10.1016/j.vaccine.2018.08.009. View

19.

Garland S, Kjaer S, Munoz N, Block S, Brown D, DiNubile M . Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016; 63(4):519-27. PMC: 4967609. DOI: 10.1093/cid/ciw354. View

20.

Liu Z, Li P, Zeng X, Yao X, Sun Y, Lin H . Impact of HPV vaccination on HPV infection and cervical related disease burden in real-world settings (HPV-RWS): protocol of a prospective cohort. BMC Public Health. 2022; 22(1):2117. PMC: 9673205. DOI: 10.1186/s12889-022-14474-1. View